In 2014, the patient experience with immunoglobulin light chain (AL) amyloidosis was not well documented in literature, and there were no existing PRO measures validated for use in studies of patients who have AL amyloidosis. In a free case study, discover how QualityMetric’s SF-36v2 health survey helped a pharmaceutical company identify critical measurement concepts for this rare disease and capture the wide variety of patient experiences, as well as their impact on other domains of patient lives.
Please answer the following questions and we will be in touch regarding your license
QualityMetric is reviewing your application and will get back to you shortly with approval to move forward with a license to administer, collect, score, and interpret the data for your project/study.
Next steps:
If you have started administering the survey, please email a copy of the survey being administered to license@qualitymetric.com. We will QA the form for any changes that may affect the scoring and interpretation of the data collected. (Fees may apply).
If you are applying for a student license, please email a copy of your student ID to license@qualitymetric.com.
In 2014, the patient experience with immunoglobulin light chain (AL) amyloidosis was not well documented in literature, and there were no existing PRO measures validated for use in studies of patients who have AL amyloidosis. In a free case study, discover how QualityMetric’s SF-36v2 health survey helped a pharmaceutical company identify critical measurement concepts for this rare disease and capture the wide variety of patient experiences, as well as their impact on other domains of patient lives.
THIS CASE STUDY WILL DISCUSS:
A novel approach to determining the patient health impact of AL amyloidosis, the SF-36v2 health survey measures a range of symptoms, experiences and patient health outcomes. This case study discusses how QualityMetric conducted in-depth interviews with clinicians, other experts and patients, as well as an online observational study, providing much-needed granularity into the consequences that AL amyloidosis has on patient lives.
